Biocon’s arm gets USFDA’s nod for Norepinephrine Bitartrate Injection

24 Mar 2025 Evaluate

Biocon’s wholly owned subsidiary -- Biocon Pharma has received approval from the U.S Food and Drug Administration (USFDA) for its ANDA Norepinephrine Bitartrate Injection USP, 4 mg/4 mL (1 mg/mL) single-dose vial. Norepinephrine bitartrate injection is indicated to raise blood pressure in adult patients with acute hypotension. The approval further adds to Biocon’s portfolio of complex drug products.

Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.

Biocon Share Price

344.70 -3.60 (-1.03%)
27-Mar-2025 13:39 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1725.25
Dr. Reddys Lab 1156.25
Cipla 1468.40
Lupin 2019.35
Zydus Lifesciences 890.35
View more..
© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.
Please wait your portfolio is updating...